Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Clarifies Expectations for Completeness Assessments for Drug Master Files

This article was originally published in The Gold Sheet

Executive Summary

FDA has clarified its requirements for DMF completeness acceptance following complaints that the draft guidance was too vague. FDA elaborates on what constitutes a single drug substance, single manufacturing process and starting materials.


Related Content

FDA Revises Guidance on DMFs and Prior Approval Supplements to Reflect GDUFA II
FDA Developing Initiatives to Improve Quality of Drug Master Files
ICH Q11 Valued for Bringing Clarity on Starting Materials, Risk Ranking





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts